BMS China Expects 90% Of Revenues From Innovative Drugs In 2017
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb’s China revenues over the next five years are expected to rely almost entirely on sales of innovative drugs, according to BMS China’s president.